Novartis to review $600m global media business

Novartis, the pharmaceutical giant, is gearing up to launch a review of its estimated $600m global media business.

Novartis: calls global media review
Novartis: calls global media review

WPP's MEC is the incumbent on the global business, including in the UK.

In 2008 Novartis consolidated its US media planning and buying into MEC after moving its business from sibling agency Mindshare in a global realignment.

The company, which has a consumer health business that markets over the counter medicines such as Tixylix and Savlon, spent £9m in the UK in the past 12 months, according to Nielsen.

Novartis, which is headquartered in Basel, Switzerland, has three other businesses called Pharmaceuticals, Vaccines and Diagnostics, and Sandoz Generics, a global supplier of generic medicines that are produced after a popular medicine's patent has expired.

Topics

Market Reports

Get unprecedented new-business intelligence with access to ±±¾©Èü³µpk10’s new Market Reports.

Find out more

Enjoying ±±¾©Èü³µpk10’s content?

 Get unlimited access to ±±¾©Èü³µpk10’s premium content for your whole company with a corporate licence.

Upgrade access

Looking for a new job?

Get the latest creative jobs in advertising, media, marketing and digital delivered directly to your inbox each day.

Create an alert now

Partner content